No Data
No Data
Sino Biopharmaceutical's Novel Lung Cancer Drug Approved in China; Shares Up 5%
Sino Biopharmaceutical (HKG:1177) said its category 1 innovative drug Benmelstobart Injection obtained approval for marketing from China's National Medical Products Administration (NMPA) as a first-li
Insiders Hold 49% of Sino Biopharmaceutical Limited (HKG:1177), and They've Been Buying Recently
Key Insights Significant insider control over Sino Biopharmaceutical implies vested interests in company growth A total of 5 investors have a majority stake in the company with 52% ownership Rece
Executive Chairwoman of the Board of Sino Biopharmaceutical Y. Y. Tse Buys 167% More Shares
Those following along with Sino Biopharmaceutical Limited (HKG:1177) will no doubt be intrigued by the recent purchase of shares by Y. Y. Tse, Executive Chairwoman of the Board of the company, who spe
Sino Biopharmaceutical Reaches Primary Endpoint for Clinical Research of Myelofibrosis Drug
Sino Biopharmaceutical's (HKG:1177) key clinical research for the registration of Rovadicitinib has met its primary endpoint, a Thursday filing on the Hong Kong bourse stated. The pharmaceutical compa
Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024
Sino Biopharmaceutical (HKG:1177) presented Phase-II Clinical Trial results for its new drug for non-small cell lung cancer (NSCLC) at the annual meeting of the American Association for Cancer Researc
News Flash: 22 Analysts Think Sino Biopharmaceutical Limited (HKG:1177) Earnings Are Under Threat
One thing we could say about the analysts on Sino Biopharmaceutical Limited (HKG:1177) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for
No Data